You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Development of an Autism Spectrum Disorder Screening Test based upon Metabolic Profiling of Fresh Blood Samples

    SBC: CIRCA BIOSCIENCE, LLC            Topic: 102

    Autism spectrum disorderASDis a neurodevelopmental disorder characterized by significant deficits in reciprocal social interactionsimpaired communication and restrictedrepetitive behaviorswith a prevalence ofinchildren in the USEarly intervention programs have been shown to be effective for improving IQlanguageand social skills for toddlers as young asmonths of ageDiagnosis of ASD is currently bas ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Nucleobase aminosugars with reduced ototoxicity

    SBC: NUBAD, LLC            Topic: Y

    PROJECT SUMMARYAminoglycosides are one of the cheapest and well known antibiotics in clinical use for overyearsbut one of the major limitations in their use is their ototoxicityWe are developing fast and low cost methods to develop aminoglycosides with antiribosomal activities and reduced toxicityIn this projectwe will identify novel aminoglycoside antibacterialsthat show reduced ototoxicityComple ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Reactor for Insect Cell Culture

    SBC: Glycan Therapeutics LLC            Topic: 300

    This fast track STTR application proposes to synthesize structurally defined heparan sulfate and chondroitin sulfate oligosaccharides for biological researchGlycan Therapeutics is a biotech company specializing in synthesizing sulfated carbohydrates using innovative enzyme based methodsThis proposal is focused on the synthesis of large authentic oligosaccharides in the size range ofmers tomersas w ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Emodin as a complementary dietary therapy to reduce toxicity of 5 fluorouracil

    SBC: AcePre, LLC            Topic: NCCIH

    PROJECT SUMMARYfluorouracilFUhas been the first choice chemotherapy drug for colorectal cancerCRCfor many yearshoweverits clinical utility remains hindered by hematopoietic and gastrointestinal toxicities resulting from its non selectivitySide effects include fatigueloss of appetiteand diarrhea among othersall of which can lead to reduced quality of lifeThe economic burden associated with chemothe ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating multi-drug resistant wound infections

    SBC: Arrevus, Inc.            Topic: NIAID

    Project SummaryOver $billion is spent annually in the US treating chronicnon healing woundsmany of which face lifethreatening complications due to infectionsWound infections are difficult to treat due to the frequency of antibiotic resistance as well as the formation of biofilmsa community of bacteria covered by an extracellular polymeric substanceBiofilm related infections can result in a substan ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Chemical Libraries Targeting Epigenetic Methyl Writers and Erasers

    SBC: Epicypher, Inc.            Topic: 102

    PROJECT SUMMARYIn this proposalEpiCypher is partnering with DrJian Jina leader in medicinal chemistry and epigenetic drug discoveryto develop the first epigenetics focused chemical library for histone methylationSmall molecule inhibitors that target histone methylation are an emerging class of therapeutics for cancer treatmentThis hot bed of drug development is fueled by the identification of nume ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Fluorescent nanofoldamers for multiplex flow cytometry

    SBC: Nirvana Sciences, Inc.            Topic: 400

    PROJECT SUMMARY ABSTRACT Polychromatic flow cytometryFCis one of the most powerful analytical techniques used in immunologybasic researchand clinical medicineIn basic researchFC is a primary tool for understanding disease development at the cellular and subcellular levelsIn the rapidly developing field of immunotherapyFC is an indispensable tool for monitoring the effectiveness of new therapies an ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Quantifying NETosis via Automated High Content Imaging Convolutional Neural Networks

    SBC: Epicypher, Inc.            Topic: NIAID

    PROJECT SUMMARY NETosis was identified as a distinct mode of cell death in neutrophils more than a decade agoDysregulation of NETosis has been implicated in the etiology of human pathologies such as preeclampsiasickle cell diseasesystemic lupus erythematosusmultiple sclerosisrheumatoid arthritissepsiscystic fibrosislupus nephritisand coagulopathies that include cancer associated thrombosisThe lite ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating multi-drug resistant bacteremia

    SBC: Arrevus, Inc.            Topic: NIAID

    Bloodstream infectionsBSIscaused by Gram negative bacterial pathogens are associated with significant morbidity and mortality due to the antibiotic resistant nature of the pathogensInfections caused by multi drug resistantMDRbacterial pathogens result in substantial health and economic impact due to the lack of effective therapeutic optionsThis lack of treatment options is particularly relevant fo ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating multi-drug resistant urinary tract infections

    SBC: Arrevus, Inc.            Topic: NIAID

    Urinary tract infectionsUTIsare one of the most common hospital acquired infections and are often caused by multi drug resistantMDRbacterial pathogensMDR bacterial pathogens are associated with significant morbidity and mortalitycreating enormous healthcare and economic burdens due to variations in disease natural histories as well as the lack of effective therapeutic optionsTreatment option limit ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government